Clinical Trials Logo

Clinical Trial Summary

This is a single-centre, non-randomised, prospective study to assess the safety of the MediSieve blood filtration system in healthy volunteers


Clinical Trial Description

The MediSieve Magnetic Haemofiltration System (MMHS) is a system to filter selected moieties from blood in an extracorporeal circuit by magnetic means. Initially, it is developed for the treatment of severe malaria to capture malaria-infected erythrocytes (who are weakly magnetic) to reduce the parasitaemia. However, the use of MMHS can be extended, with the use of antibodies coupled to magnetic beads, to other diseases, such as sepsis. The MMHS has to be used first in healthy volunteers to determine its clinical safety. To this end, 6 healthy male and female volunteers (ratio 1:1) will undergo blood filtration using the MediSieve Magnetic Haemofiltration System (without magnetic beads) for five consecutive hours. Vital signs will be continuously monitored and blood samples will be obtained serially to determine laboratory safety and immunological parameters. Furthermore, volunteers will have two follow up visits at 24 hours and 7 days post filtration. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05713188
Study type Interventional
Source MediSieve Limited
Contact
Status Completed
Phase Phase 1
Start date June 13, 2022
Completion date November 30, 2022

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03853005 - Effect of High volumeHemodiafiltration on Lung Oxygenation and Mechanics N/A
Withdrawn NCT03786536 - Safety and Initial Performance of the MediSieve Magnetic Haemofiltration System N/A